Theratechnologies (TH) Sets New 12-Month Low at $6.69
Theratechnologies Inc (TSE:TH)’s share price reached a new 52-week low on Tuesday . The stock traded as low as C$6.69 and last traded at C$6.75, with a volume of 121456 shares changing hands. The stock had previously closed at C$6.97.
Several equities analysts have recently weighed in on TH shares. National Bank Financial reduced their price objective on shares of Theratechnologies from C$14.25 to C$12.75 and set an “outperform” rating for the company in a research report on Thursday, February 21st. Royal Bank of Canada reduced their price objective on shares of Theratechnologies from C$12.00 to C$10.00 and set a “sector perform” rating for the company in a research report on Friday, February 22nd. Finally, Echelon Wealth Partners restated a “buy” rating on shares of Theratechnologies in a research report on Friday, February 22nd.
The firm has a market capitalization of $536.01 million and a P/E ratio of -138.16. The company has a current ratio of 2.46, a quick ratio of 1.97 and a debt-to-equity ratio of 145.32.
An institutional investor recently bought a new position in Theratechnologies stock. Virtu Financial LLC bought a new position in Theratechnologies Inc (TSE:TH) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,119 shares of the company’s stock, valued at approximately $96,000.
COPYRIGHT VIOLATION NOTICE: This report was posted by Marea Informative and is the sole property of of Marea Informative. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.mareainformativa.com/news/2019/04/23/theratechnologies-th-sets-new-12-month-low-at-6-69.html.
Theratechnologies Company Profile (TSE:TH)
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.
Featured Article: How to calculate the annual rate of depreciation
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.